AIMS: Retrospective database study comparing upper and lower airway-related outcomes for patients with rhinitis and co-morbid asthma receiving mometasone furoate--an intranasal corticosteroid with low systemic bioavailability--or an oral antihistamine. METHODS: 395 patients prescribed intranasal mometasone were matched on 10 demographic and respiratory-related criteria in a 1:2 ratio to 790 patients prescribed oral antihistamine. Asthma and rhinitis control were assessed over one year using predefined composite proxy measures. RESULTS: Asthma control was achieved by 309/395 (78.2%) versus 580/790 (73.4%; p=0.071) patients in the mometasone and antihistamine cohorts, respectively. Rhinitis control was achieved by 293 (74.2%) versus 539 (68.2%; p=0.035), respectively. The adjusted odds ratios for antihistamines, relative to mometasone, were 0.71 (95% CI, 0.52-0.98) for achieving asthma control and 0.74 (95% CI, 0.56-0.97) for achieving rhinitis control. CONCLUSIONS: Patients with rhinitis and co-morbid asthma initiating rhinitis therapy achieved significantly better upper as well as lower airway outcomes with intranasal mometasone than with oral antihistamine.
AIMS: Retrospective database study comparing upper and lower airway-related outcomes for patients with rhinitis and co-morbid asthma receiving mometasone furoate--an intranasal corticosteroid with low systemic bioavailability--or an oral antihistamine. METHODS: 395 patients prescribed intranasal mometasone were matched on 10 demographic and respiratory-related criteria in a 1:2 ratio to 790 patients prescribed oral antihistamine. Asthma and rhinitis control were assessed over one year using predefined composite proxy measures. RESULTS:Asthma control was achieved by 309/395 (78.2%) versus 580/790 (73.4%; p=0.071) patients in the mometasone and antihistamine cohorts, respectively. Rhinitis control was achieved by 293 (74.2%) versus 539 (68.2%; p=0.035), respectively. The adjusted odds ratios for antihistamines, relative to mometasone, were 0.71 (95% CI, 0.52-0.98) for achieving asthma control and 0.74 (95% CI, 0.56-0.97) for achieving rhinitis control. CONCLUSIONS:Patients with rhinitis and co-morbid asthma initiating rhinitis therapy achieved significantly better upper as well as lower airway outcomes with intranasal mometasone than with oral antihistamine.
Authors: Kerry L Hancock; Sinthia Bosnic-Anticevich; John D Blakey; Mark Hew; Li Ping Chung; Biljana Cvetkovski; Scott Claxton; Peter Del Fante; Eve Denton; Joe Doan; Kanchanamala Ranasinghe; Lucy Morgan; Anita Sharma; Peter K Smith; Deb Stewart; Philip J Thompson; Russell Wiseman; John W Upham; Kwok Y Yan; Victoria Carter; Kiranjeet Dhillon; Florian Heraud; Thao Le; Rebecca Vella; David Price Journal: Pragmat Obs Res Date: 2022-07-05
Authors: Hilda J I De Jong; Jaco Voorham; Glenis K Scadding; Claus Bachert; Giorgio Walter Canonica; Peter Smith; Ulrich Wahn; Dermot Ryan; Jose A Castillo; Victoria A Carter; Ruth B Murray; David B Price Journal: World Allergy Organ J Date: 2020-12-19 Impact factor: 4.084